The anti-peg immune response: Fact, fiction, or a legitimate concern for biomaterials? Conference Paper uri icon


  • 2019 Omnipress - All rights reserved. Statement of Purpose: Poly(ethylene glycol) (PEG) is commonly used in pharmaceuticals, drug delivery, and tissue regeneration. For tissue engineering specifically, PEG is widely considered to be a biologically inert blank slate" that can be programmed with cell-instructive cues. However, there are growing concerns of PEG immunogenicity. Antibodies against PEG have been linked to the accelerated blood clearance of PEGylated therapeutics, and anaphylaxis like reactions have been noted in patients who have taken PEG or have been administered PEGylated pharmaceuticals. In addition, a 2016 study found that 24% of healthy human subjects had PEG antibodies. It has been suggested that the antibody-antigen complex causes hypersensitivity through activation of the complement cascade. Concerning the recent findings, there is a need to investigate how PEG anti-PEG antibody interactions affect the biological response to PEG hydrogels, which is the objective of this study.

published proceedings

  • Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium

author list (cited authors)

  • Isaac, A., Winklepleck, V., & Alge, D.

complete list of authors

  • Isaac, A||Winklepleck, V||Alge, D

publication date

  • January 2019